Pfizer backs diabetes research award program

Global drug giant Pfizer and the European Foundation for the Study of Diabetes announced t at the European Association for the Study of Diabetes Annual Meeting, held in Amsterdam, the Netherlands, the development of a new awards program which will provide research grants to support European work around understanding and reducing cardiovascular risk in patients with diabetes.

Grants will be awarded for, but not limited to, research focusing on fostering a clearer understanding of the best cardiovascular risk-reduction strategies, such as educational programs, risk-assessment tools, screenings and clinical interventions.

Lance Berman, senior medical director at Pfizer, said: "as part of our commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce these risks, further our understanding of optimal treatment options, and ultimately improve the lives of the people with diabetes."